Dear Editor,
Intracranial neoplasm (IN) are currently considered as a contraindication for intravenous (IV) thrombolysis in acute ischemic stroke (AIS) patients due to a hypothetical potential increase in the risk of intracranial hemorrhage (ICH) and based on expert opinions (1).
An 83-year-old woman developed sudden onset rightsided hemiparesis and aphasia. She presented to another hospital in our region within the first 3 hours after symptom onset and was found to have disabling neurological deficits with a national institute of health stroke scale (NIHSS) of 19. initial non-contrast head computed tomography (NCHCT) at the other hospital was read as "no acute abnormality". We only had access to the report of the initial NCHCT and were not able to review the image. She had no obvious contraindication for IV recombinant tissue plasminogen activator (rtPA). She received IV rtPA based on the standard protocol 1 and afterwards, she was transferred to our medical center for higher level of care. She arrived in our emergency department 6 hours after the symptom onset when she was found to have improvement in her language function and her NIHSS decreased to 14. A NCHCT was done right after she got to our hospital which did not show any evidence of ICH but showed a 1.4 cm midline hyperdense mass suggestive of a planum sphenoidale meningioma. Brain Magnetic Resonance Imaging (MRI) with and without gadolinium was performed 6 hours later which demonstrated acute infarcts in the left frontal lobe. In addition, brain MRI revealed 2 meningiomas. There was a 2.2 cm homogeneous enhancing mass of the planum sphenoidale, compatible with meningioma. Additionally, there was a small 0.9 cm enhancing nodule involving the left frontal convexity, compatible with meningioma (Figure 1) . NCHCT was repeated in 24 hours after IV rtPA administration which did not show ICH or hemorrhage within the neoplasms. Within next 48 hours, NIHSS improved to 9 and then to 4 on the day of discharge.
A computerized search in Medline, Pubmed and Google scholar till April 2014, revealed only 8 cases reported of IV thrombolysis in patients with benign Ins (2-5).
Four were for AIS, 3 for myocardial infarction and one for a suspected stroke, which turned out to be a low-grade astrocytoma. Of the 4 cases that received IV rtPA for AIS, one had an acoustic schwannoma and 3 had a meningioma with no ICH post IV rtPA (2-4). Among the 3 patients who received IV thrombolysis for myocardial infarction, one had a pituitary adenoma and 2 had one meningioma each, neither developed ICH post IV thrombolysis (5) .
To the best of our knowledge, this is the first reported patient of AIS who received IV rtPA and had more than one IN, both were meningiomas. Our case confirms the previous literature that the presence of benign IN does not increase the risk of ICH in AIS patients who receive IV rtPA. 
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